Related Experiment Video
Updated: Aug 13, 2026

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors
Published on: October 30, 2016
ACAM2000 vaccine safety and immunogenicity considerations for smallpox and mpox
Vanja Komlenovic1, James McCarty2, David Cassie1
1Clinical Development, Emergent BioSolutions Canada Inc.,Winnipeg, MB, Canada.
Introduction:
Smallpox, eradicated globally in 1980, remains a major biodefense concern due to retained Variola virus stocks and the absence of population immunity following cessation of routine vaccination. Monkeypox virus (MPXV), a related orthopoxvirus, has reemerged as a global public health threat, with major outbreaks in 2022 and renewed spread from 2024 onward.
Areas Covered:
This review evaluates ACAM2000®, a second-generation live smallpox vaccine, summarizing its development, immunogenicity, efficacy, safety, regulatory status, and potential role in mpox prevention.
Expert Opinion:
ACAM2000 remains a critical medical countermeasure for smallpox preparedness and a valuable, though selective, tool for mpox prevention. Its high immunogenicity, rapid protection, and broad orthopoxvirus coverage must be balanced against a well-characterized safety risk profile.
Related Concept Videos
Smallpox
Cross-reactivity
Vaccines
Vaccinations
Chickenpox
Vaccine Production

